Skip to main content
Funded Studies

Kimberley S. Gannon, PhD

Senior Vice President, Preclinical Research & Development at NeuroPhage Pharmaceuticals, Inc.

Location: Cambridge, MA United States

Dr. Gannon received a PhD in neuroscience from Florida State University in 1994 and conducted her post-doctoral training at Hoffmann-La Roche in the Institute of Molecular Biology (Nutley, NJ) and Mount Sinai School of Medicine in the Department of Physiology and Biophysics (New York, NY). Although experienced in all aspects of drug development, her main areas of expertise are preclinical efficacy, translational research and nonclinical safety. She has worked extensively in the pharmaceutical industry, holding positions at SmithKline Beecham, Eli Lilly and EPIX Pharmaceuticals. Dr. Gannon joined NeuroPhage in October 2009 and oversees preclinical R&D. Her main focus is currently on the development of NPT001 for neurodegenerative diseases such as Alzheimer´s disease and Parkinson´s disease.

Associated Grants

  • Effect of NPT088 in Alpha-synuclein Overexpressing Models


  • Characterization of NPT001-mediated Alpha-Synuclein Disaggregation and Clearance


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.